A randomized controlled trial is designed to compare troglit…
A randomized controlled trial is designed to compare troglitazone to placebo as adjunct therapy to insulin in patients with type 1 diabetes. The trial had a primary outcome is A1c and patients have a goal of an A1c of 7% or less. The investigators determined they needed to enroll 327 participants to achieve 80% power to detect a 0.5% decrease in A1c with a one-sided alpha level of 0.05. What is the null hypothesis for this trial?
Read Details